Gilead Sciences | GILD - Należności Handlowe





Należności Handlowe Zmiana Data
AbbVie USD 12.59B 180M 2025-12
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
ALKERMES USD 407.63M 73.6M 2026-03
Alnylam Pharmaceuticals USD 883.96M 106.39M 2026-03
Amgen USD 9.14B 432M 2026-03
Biogen USD 1.79B 76.6M 2026-03
BioMarin Pharmaceutical USD 903.91M 4.3M 2026-03
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Coherus Biosciences USD 18.42M 232.08M 2025-12
Eli Lilly USD 21.18B 1.02B 2026-03
Gilead Sciences USD 4.74B 172M 2026-03
GlaxoSmithKline GBP 7.94B 178M 2026-03
Glaxosmithkline GBP 10.45B 707.81M 2025-12
Incyte USD 1.05B 27.09M 2026-03
J&J USD 21.33B 3.72B 2025-12
Merck USD 11.78B 345M 2025-12
Moderna USD 71M 113M 2026-03
Neurocrine Biosciences USD 768.1M 81.3M 2026-03
Novartis USD 9.6B 2.69B 2026-03
Pfizer USD 16.17B 332M 2026-03
PTC Therapeutics USD 181.62M 21.45M 2025-12
Puma Biotechnology USD 28.1M 3.52M 2024-06
Regeneron Pharmaceuticals USD 5.73B 10.1M 2026-03
Sangamo BioSciences USD 581K 110K 2024-06
Sanofi EUR 482M 85M 2026-03
Sarepta Therapeutics USD 547.91M 149.68M 2026-03
United Therapeutics USD 312M 38.2M 2026-03
Vertex Pharmaceuticals USD 2B 56.7M 2026-03